{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:14:38Z","timestamp":1762431278577},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Adjuvant therapy choice for women with FIGO stage III endometrial carcinoma (EC) is controversial. We investigate the comparative benefit of adjuvant chemotherapy (CT) alone, radiation therapy alone (RT) or in combination (chemotherapy and radiation therapy [CRT]) with respect to recurrence-free survival (RFS) and overall survival (OS) in women with pelvis-limited (PL) EC (stage IIIA, IIIB, and IIIC1).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>A multi-institutional database of 270 surgically staged women with PLEC was analyzed. Univariate log-rank analyses and Cox regression multivariate analyses (MVA) were performed to identify factors associated with RFS and OS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Median RFS and OS were 112 and 130 months, respectively, for the full cohort. Adjuvant treatment was CT in 21%, RT in 27%, and CRT in 47%. Age, year of treatment, grade, histology, and adjuvant treatment were significantly associated with RFS and OS on univariate analysis. PLEC patients receiving CT alone fared worse in terms of RFS (<jats:italic toggle=\"yes\">P=<\/jats:italic>0.07 relative to RT and &lt;0.01 relative to CRT). On MVA, CRT retained significantly improved RFS relative to CT (hazard ratio for recurrence 0.38, <jats:italic toggle=\"yes\">P&lt;<\/jats:italic>0.01). PLEC patients receiving RT or CRT had improved OS compared with CT, <jats:italic toggle=\"yes\">P&lt;<\/jats:italic>0.01 and 0.03, respectively. On MVA, both RT only and CRT retained association with improved OS relative to CT alone (hazard ratio for death, 0.43, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.02 and 0.40, <jats:italic toggle=\"yes\">P&lt;<\/jats:italic>0.01, respectively).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>For surgically staged PL stage III EC, treatment regimens incorporating RT were associated with improved survival endpoints relative to CT alone. As such, RT should be considered an important component in the adjuvant management of stage III PLEC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000371","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T15:09:50Z","timestamp":1487776190000},"page":"792-796","source":"Crossref","is-referenced-by-count":8,"title":["Adjuvant External Radiation Impacts Outcome of Pelvis-limited Stage III Endometrial Carcinoma"],"prefix":"10.1097","volume":"41","author":[{"given":"Kevin","family":"Albuquerque","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology"}]},{"given":"Michael","family":"Folkert","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology"}]},{"given":"Jyoti","family":"Mayadev","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Davis Comprehensive Cancer Center, University of California, Sacramento, CA"}]},{"given":"Alana","family":"Christie","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology"}]},{"given":"Margaret R.","family":"Liotta","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology"}]},{"given":"Christa","family":"Nagel","sequence":"additional","affiliation":[{"name":"Department Gynecological Oncology, UH Case Medical Center, Cleveland, OH"}]},{"given":"Parag","family":"Sevak","sequence":"additional","affiliation":[{"name":"Henry Ford Hospital, Division of Radiation Oncology, Detroit, MI"}]},{"given":"Matthew M.","family":"Harkenrider","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology"}]},{"given":"Jayanthi S.","family":"Lea","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology"}]},{"given":"Rabbie K.","family":"Hanna","sequence":"additional","affiliation":[{"name":"Henry Ford Hospital, Division of Radiation Oncology, Detroit, MI"}]},{"given":"William C.","family":"Small","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Loyola University Chicago, Maywood, IL"}]},{"given":"David S.","family":"Miller","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology"}]},{"given":"Xian-Jin","family":"Xie","sequence":"additional","affiliation":[{"name":"Biostatistics, UT Southwestern Medical Center, Dallas, TX"}]},{"given":"Ronald K.","family":"Potkul","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology"}]},{"given":"Mohamed A.","family":"Elshaikh","sequence":"additional","affiliation":[{"name":"Henry Ford Hospital, Division of Radiation Oncology, Detroit, MI"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijgo.2009.02.009","article-title":"Revised FIGO staging for carcinoma of the cervix","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int J Gynecol Obstet"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3802\/jgo.2014.25.2.136","article-title":"Adjuvant therapy for endometrial cancer","volume":"25","author":"DeLeon","year":"2014","journal-title":"J Gynecol Oncol"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.2004.00.7617","article-title":"Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"24","author":"Randall","year":"2006","journal-title":"J Clin Oncol"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6603279","article-title":"Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial","volume":"95","author":"Maggi","year":"2006","journal-title":"Br J Cancer"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/COC.0000000000000098","article-title":"ACR appropriateness criteria\u00ae advanced stage endometrial cancer","volume":"37","author":"Elshaikh","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/1754-9485.12447","article-title":"Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial","volume":"60","author":"Jameson","year":"2016","journal-title":"J Med Imaging Radiat Oncol"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1006\/gyno.2002.6789","article-title":"Stage IIIC endometrioid corpus cancer includes distinct subgroups","volume":"87","author":"Mariani","year":"2002","journal-title":"Gynecol Oncol"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.2001.19.20.4048","article-title":"Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study","volume":"19","author":"Hoskins","year":"2001","journal-title":"J Clin Oncol"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijrobp.2006.08.006","article-title":"Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach","volume":"67","author":"Lupe","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ygyno.2007.09.025","article-title":"Pilot phase II trial of radiation \u201csandwiched\u201d between combination paclitaxel\/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC)","volume":"108","author":"Fields","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3802\/jgo.2015.26.4.284","article-title":"Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer","volume":"26","author":"Signorelli","year":"2015","journal-title":"J Gynecol Oncol"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ygyno.2009.06.035","article-title":"Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation","volume":"115","author":"Klopp","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2013.06.024","article-title":"Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin\/paclitaxel for stage III (FIGO 2009) endometrial cancer","volume":"130","author":"Milgrom","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ygyno.2008.11.014","article-title":"A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study","volume":"112","author":"Homesley","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ygyno.2006.02.007","article-title":"Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin\/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer","volume":"103","author":"Greven","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.ejca.2010.06.002","article-title":"Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer\u2014results from two randomised studies","volume":"46","author":"Hogberg","year":"2010","journal-title":"Eur J Cancer"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ygyno.2009.06.005","article-title":"A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer","volume":"114","author":"Secord","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2012.10.010","article-title":"A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer","volume":"128","author":"Secord","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ygyno.2014.02.019","article-title":"Improving oncologic outcomes for women with endometrial cancer: realigning our sights","volume":"133","author":"Dowdy","year":"2014","journal-title":"Gynecol Oncol"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ygyno.2013.03.011","article-title":"Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas","volume":"129","author":"Ayeni","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ygyno.2016.03.021","article-title":"Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: patterns of care and impact on overall survival","volume":"141","author":"Boothe","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201808000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T03:06:25Z","timestamp":1693710385000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201808000-00011"}},"subtitle":["A Multi-institutional Study"],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000371","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}